Time to forge ahead: The Internet of Things for healthcare

Situated at the intersection of technology and medicine, the Internet of Things (IoT) holds the promise of addressing some of healthcare's most pressing challenges, from medical error, to chronic drug shortages, to overburdened hospital systems, to dealing with the COVID-19 pandemic. However, despite considerable recent technological advances, the pace of successful implementation of promising IoT healthcare initiatives has been slow. To inspire more productive collaboration, we present here a simple—but surprisingly underrated—problem-oriented approach to developing healthcare technologies. To further assist in this effort, we reviewed the various commercial, regulatory, social/cultural, and technological factors in the development of the IoT. We propose that fog computing—a technological paradigm wherein the burden of computing is shifted from a centralized cloud server closer to the data source—offers the greatest promise for building a robust and scalable healthcare IoT ecosystem. To this end, we explore the key enabling technologies that underpin the fog architecture, from the sensing layer all the way up to the cloud. It is our hope that ongoing advances in sensing, communications, cryptography, storage, machine learning, and artificial intelligence will be leveraged in meaningful ways to generate unprecedented medical intelligence and thus drive improvements in the health of many people.

Parkinsonism as a Third Wave of the COVID-19 Pandemic?

Since the initial reports of COVID-19 in December 2019, the world has been gripped by the disastrous acute respiratory disease caused by the SARS-CoV-2 virus. There are an ever-increasing number of reports of neurological symptoms in patients, from severe (encephalitis), to mild (hyposmia), suggesting the potential for neurotropism of SARS-CoV-2. This Perspective investigates the hypothesis that the reliance on self-reporting of hyposmia has resulted in an underestimation of neurological symptoms in COVID-19 patients. While the acute effect of the virus on the nervous system function is vastly overshadowed by the respiratory effects, we propose that it will be important to monitor convalescent individuals for potential long-term implications that may include neurodegenerative sequelae such as viral-associated parkinsonism. As it is possible to identify premorbid harbingers of Parkinson's disease, we propose long-term screening of SARS-CoV-2 cases post-recovery for these expressions of neurodegenerative disease. An accurate understanding of the incidence of neurological complications in COVID-19 requires long-term monitoring for sequelae after remission and a strategized health policy to ensure healthcare systems all over the world are prepared for a third wave of the virus in the form of parkinsonism.